Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 11/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29588404 | 0.88 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2TSHRKMT2AACACB | |
| SCHEMBL22587894 | 0.88 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2TSHRKMT2AACACB | |
| SCHEMBL29469921 | 0.82 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2TSHRKMT2AALPL | |
| SCHEMBL24313728 | 0.82 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2TSHRKMT2AALPL | |
| SCHEMBL17811838 | 0.81 | ACACB (0.41) | ACACB | |
| SCHEMBL17811813 | 0.79 | ACACB (0.39) | ALDH1A1SMN1; SMN2ACACB | |
| SCHEMBL24313897 | 0.78 | ACACB (0.38) | ACACB | |
| SCHEMBL29469892 | 0.78 | ACACB (0.38) | ACACB | |
| SCHEMBL24314212 | 0.78 | ACACB (0.39) | ACACBBRD4 | |
| SCHEMBL741127 | 0.77 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2TSHRKMT2AALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022081842-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081807-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |